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Abstract
Background: Conventional methods for lung cancer detection including computed
tomography (CT) and bronchoscopy are expensive and invasive. Thus, there is still
a need for an optimal lung cancer detection technique.
Methods: The exhaled breath of 50 patients with lung cancer histologically proven
by bronchoscopic biopsy samples (32 adenocarcinomas, 10 squamous cell
carcinomas, 8 small cell carcinomas), were analyzed using ion mobility
spectrometry (IMS) and compared with 39 healthy volunteers. As a secondary
assessment, we compared adenocarcinoma patients with and without epidermal
growth factor receptor (EGFR) mutation.
Results: A decision tree algorithm could separate patients with lung cancer
including adenocarcinoma, squamous cell carcinoma and small cell carcinoma.
One hundred-fifteen separated volatile organic compound (VOC) peaks were
analyzed. Peak-2 noted as n-Dodecane using the IMS database was able to
separate values with a sensitivity of 70.0% and a specificity of 89.7%. Incorporating
a decision tree algorithm starting with n-Dodecane, a sensitivity of 76% and
specificity of 100% was achieved. Comparing VOC peaks between
adenocarcinoma and healthy subjects, n-Dodecane was able to separate values
with a sensitivity of 81.3% and a specificity of 89.7%. Fourteen patients positive for
EGFR mutation displayed a significantly higher n-Dodecane than for the 14 patients
negative for EGFR (p,0.01), with a sensitivity of 85.7% and a specificity of 78.6%.
Conclusion: In this prospective study, VOC peak patterns using a decision tree
algorithm were useful in the detection of lung cancer. Moreover, n-Dodecane
analysis from adenocarcinoma patients might be useful to discriminate the EGFR
mutation.
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Introduction
Recently the National Lung Screening Trial team reported that screening with low
dose computed tomography (CT) reduced the mortality of lung cancer by about
20%. Low dose CT is an important screening test; however, it is expensive and
there are risks associated with radiation exposure. On the other hand, breath
analysis is easy-to-use and radiation-free. Gas chromatography and mass-
spectrometry (GC/MS) [1–2] and chemical sensor matrices: quartz microbalance
[3], surface acoustic wave [4], carbon-polymer array [5], colorimetric sensor [6],
single-walled carbon nanotube [7] and gold nanoparticles [8], can detect volatile
organic compounds (VOCs) in lung cancer from human breath. In addition,
canine scent has focused on the diagnosis of lung cancer [9–10].
Ion mobility spectrometry (IMS) with multi-capillary column (MCC), a breath
analysis device, can detect specific VOCs in patients with lung cancer [11]. IMS/
MCC can detect a very low concentration of VOCs (normally in the ppbv- to
pptv-range, pg/L to ng/L-range) in less than 8 minutes total analysis time and is
superior to GC/MS as it can be applied at the bed-site and direct sampling can be
taken without preparation [11–21]. In Europe, 550 MBq b-radiation sources are
acceptable; however, for the Japanese market, regulations restrict 63Ni b-radiation
sources to under 100 MBq. Therefore in this study, a 95 MBq ß-ionization source
was used. The initial aim of this study is to confirm the reproducibility of IMS/
MCC results (using BioScout: B&S Analytik, Dortmund, Germany) for a Japanese
population.
Chemotherapy of lung cancer patients depends upon performance status,
histological features, tumor staging, and molecular characteristics. Previously, 2
drugs combination chemotherapy including platinum has been performed as a
first-line treatment for patients with advanced non-small cell lung cancer
(NSCLC) considered as a single disease despite of its histologic and molecular
heterogeneity. However, recently, the discovery of molecular abnormalities such
as epidermal growth factor receptor (EGFR) mutation, and new agents such as
EGFR tyrosine kinase inhibitor changed treatment of NSCLC. These led NSCLC
treatment to the personalized therapy. Differences of histologic type and genetic
alterations are the most important factors in decision of current lung cancer
treatment. The second aim of this study is to confirm whether VOC patterns are
able to detect histologically confirmed lung cancers, and driver mutations such as
EGFR mutation.
Methods
Breath analysis using an ion mobility spectrometer (IMS) was randomly
performed in healthy volunteers and patients with lung cancer at St. Marianna
University School of Medicine from 1 September 2011 to 14 January 2013. In all
patients with lung cancer, breath samples were collected before bronchoscopy.
The Ethics Committee of St. Marianna University School approved this study and
written informed consent was obtained from all subjects (No1820). This study was
Lung Cancer Detection by IMS
PLOS ONE | DOI:10.1371/journal.pone.0114555 December 9, 2014 2 / 13
registered with the University Hospital Medical Information Network Clinical
Trial Registry (UMIN-CTR) (UMIN000006696, 000008328).
The exhaled breath of 50 patients (31 men, 19 women), with lung cancer
confirmed histologically by bronchoscopic biopsy specimen was compared with
39 healthy volunteers (25 men, 14 women). Smoking histories of subjects were
measured using pack-years.
Ion mobility spectrometry (IMS)
IMS (BioScout, B&S Analytik, Dortmund, Germany) combined with a multi-
capillary column (MCC, type OV-5, Multichrom Ltd, Novosibirsk, Russia) and
coupled to a spirometer (Ganhorn Medizin Electronic, Niederlauer, Germany), as
a CO2-controlled sample inlet unit was utilized. Table 1 shows the characteristics
of ion mobility spectrometer.
The major parameters of breath analysis have been previously summarized [11–
21] and will be discussed here in brief. IMS refers to the detection of ions formed
from analysis at ambient pressure within a drift tube. The term ion mobility
spectrometry refers to the method characterizing analysis in gases by their gas
phase ion mobility. Normally, the drift time of ion swarms, formed using suitable
ionization sources then passing through electrical shutters, are measured. Ion
mobility for analysis can provide a means for detecting and identifying vapors.
The drift velocity is related to the electric field strength by the mobility. Therefore,
the mobility is proportional to the inverse drift time, which will be measured at a
fixed drift length. IMS combines both high sensitivity and relatively low technical
expenditure with a high-speed data acquisition. The time to acquire a single
spectrum is in the range of 10 ms to 100 ms. Thus, IMS is an instrument suitable
for process control, but due to the occurrence of ion-molecule reactions and
relatively poor resolution of the species formed, it is generally not for
identification of unknown compounds. Compared with mass spectrometry, the
mean free path of the ions is much smaller as the dimensions of the instrument.
An ion formed has a high number of collisions with carrier gas molecules on the
drift way towards the Faraday-plate. However, because of the high vacuum
conditions in mass spectrometry, an ion formed there will normally have no
collision with other molecules during the drift. In the small time gap between the
collisions the ion will gain energy from the external electric field and lose the
energy by the next collision process. Consequently, a rather constant drift velocity
will be reached. Therefore, an ion swarm drifting under such conditions
experiences a separation process that is based on different drift velocities of ions
with different masses or geometrical structures. Collection of these ions on a
Faraday-plate delivers a time dependent signal corresponding to the mobility of
the arriving ions. Such an ion mobility spectrum contains information on the
nature of the different compounds present in the sample gas.
Compared to other analytical methods, IMS has a significantly large
information density with comparative low burden in weight, power and size.
Naturally, there are other analytical techniques, which contain much greater
Lung Cancer Detection by IMS
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information density like mass spectrometry. Other techniques are smaller and
more economical on power like surface acoustic wave sensors. IMS shows its
specificity depending on ion size, chemistry and nature of the sample. It can be
very high, through a combination of drift time and ionization properties. When it
is always possible, hyphenated GC-IMS are preferred. By itself IMS is superior to
MS and GC with respect to utilities, gas consumption, no vacuum is required and
relatively low power requirements.
For spectrometry, a 95 MBq 63Ni ß-radiation source was applied for the
ionization of carrier gas (synthetic air). Generally, the total number of ions
formed is slightly lower using 95 MBq compared to 550 MBq. As a result, the
total number of ions with the reactant ion peak in synthetic air will decrease the
linear range marginally. For application cases like breath analysis mostly working
on detection limits of analysis, the occurrence of analysis plays a more important
role than the linear range. As shown later in this paper, the discrimination power
and the detectability of the analyses in exhaled breath are not affected by the
difference in the activity of the ionization source.
The spectrometer was connected to a polar MCC that functioned as a pre-
separation unit. For MCC, the analyses of exhaled breath were sent through 1000
parallel capillaries, each with an inner diameter of 40 mm and a film thickness of
200 nm. The total diameter of the separation column was 3 mm.
The exhaled breath of subjects was taken directly through the spirometer using
a standard mouthpiece containing an ultrasonic sensor without registering the
500 mL of dead volume on expiration. The contents of a 10 mL sample loop were
added to the inlet of the MCC and transported to IMS, which was directly
connected to the ionization region after pre-separation. The MCC and drift tube
were held at 40 C˚. The carrier and drift gas used was synthetic air (Nippon
Megacare, Tokyo, Japan).
Table 1. Characteristics of ion mobility spectrometer (BioScout).
Parameters BioScout
Ionization source 63Ni (95 MBq)
Electric field strength 320 V/cm
Length of drift region 12 cm
Diameter of drift region 15 mm
Length of ionization chamber 15 mm
Shutter opening time 300 ms
Shutter impulse time 100 ms
Drift gas Synthetic air
Drift gas flow 100 … 300 mL/min
Temperature Room temperature
Pressure 101 kPa (ambient pressure)
MCC OV-5, polar
Column temperature 40˚C isotherm
doi:10.1371/journal.pone.0114555.t001
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Statistical analysis
The peaks were characterized using Visual Now 2.2 software (B&S Analytik,
Dortmund Germany) [14],[22–25]. All peaks found were characterized by their
position with drift time (corresponding 1/K0-value) and retention time, and their
concentration related to the peak height (table 1). Details of the data analysis
procedure were realized based on the methods described in detail previously
[15],[22–26] and summarized here [27–31].
For the different groups and each of the peaks, Box-and-Whisker plots were
generated. The rank sum was provided by Wilcoxon-Mann-Whitney test using
Bonferroni correction. Visual Now 2.2 was used to rank the peaks with the highest
difference between groups.
The relation between the peaks found in BioScout and the analysis was realized
by comparison using the Visual Now Version 110801 database (B&S Analytik,
Dortmund, Germany), obtained by measurements described previously [11], [32–
34]. In the present paper, peaks were correlated with the nearest analysis from the
reference database and compared to the actual position of the peak.
Results
All lung cancers were histologically proven by bronchoscopic biopsy samples. In
28 patients, transbronchial biopsy in peripheral pulmonary lesions using both
endobronchial ultrasonography with guide-sheath and virtual bronchoscopic
navigation was confirmed. In 22 patients, centrally located tracheobronchial
lesions could be directly confirmed. The types of lung cancer were: 32
adenocarcinomas, 10 squamous cell carcinomas and 8 small cell carcinomas. Of
32 patients with adenocarcinoma, 14 were found to be positive for the EGFR
mutation, 14 were negative for the EGFR mutation and 4 patients were positive
for anaplastic lymphoma kinase (ALK) fusion. Lung cancer TNM staging showed:
stage 1513 patients, stage 256 patients, stage 358 patients and stage 4523
patients. Seven of 39 healthy volunteers and 33 of 50 patients with lung cancer had
smoking histories (table 2).
A total of 115 different peaks were compared with respect to the separation
power in patients with lung cancer and healthy volunteers (Fig. 1). Ten VOC
peaks were identified with significance higher than 95% (p,0.01) in patients with
lung cancer. Of these, peak-2, which has the strongest VOC peak, is noted as the
n-Dodecane using the IMS database and was able to separate values with a
sensitivity of 70.0% and a specificity of 89.7%. The 9 other VOC peaks were also
identified using the database (table 3). In addition, using a decision tree algorithm
with n-Dodecane as starting point, a sensitivity of 76%, specificity of 100%, PPV
of 100% and NPV of 76.4% were recorded (Fig. 2).
Comparing VOC peaks between adenocarcinoma and healthy subjects, 11 VOC
peaks were found to have significance higher than 95% (p,0.01) and n-Dodecane
(peak-2) was able to separate values with a sensitivity of 81.3% and a specificity of
89.7% (Fig. 3). In addition, 14 lung adenocarcinoma patients positive for EGFR
Lung Cancer Detection by IMS
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Table 2. Characteristics of patients.
Healthy Lung cancer
Sex
Male 25 31
Female 14 19
Age 32¡8 68¡10
Pathological type
adenocarcinoma 32
EGFR mutation (+) 14
EGFR mutation (2) 14
ALK fusion (+) 4
squamous cell carcinoma 10
small cell carcinoma 8
Tumor stage
I (IA, IB) 13 (7, 6)
II (IIA, IIB) 6 (3, 3)
III (IIIA, IIIB) 8 (4, 4)
IV 23
Tumor Location
Central 22
Peripheral 28
Smoking in pack-years 4.0¡9.4 31.7¡28.3
doi:10.1371/journal.pone.0114555.t002
Fig. 1. IMS chromatogram in a healthy volunteer. One hundred-fifteen VOC peaks were detected with ion
mobility spectrometry in patients with lung cancer and healthy volunteers.
doi:10.1371/journal.pone.0114555.g001
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mutation displayed a significantly higher n-Dodecane VOC peak than for 14 lung
adenocarcinoma patients negative for the EGFR mutation without 4 patients
positive for ALK fusion (p,0.01), with a sensitivity of 85.7% and a specificity of
78.6% (Figs. 4 and 5).
Comparing VOC peaks between squamous cell carcinoma and the healthy
group, 11 VOC peaks were found to have significance higher than 95% and peak-
69 was able to separate the best value with a sensitivity of 97.4 and a specificity of
Table 3. Detection of VOC peaks using Visual Now database.
Peak Description 1/K0 RT P value
2 n-Dodecane 0.891 128.9 ,0.001
6 3-Methy1-15Butanol 0.737 11.0 ,0.001
11 2-Metylbutylacetat or 2-Hexanol 0.631 12.4 ,0.001
22 Cyclohexanon 0.564 11.6 ,0.01
23 Iso-propylamin 0.587 3.0 ,0.01
37 n-Nonal or Cyclohexanon 0.716 10.4 ,0.001
76 Ethylbenzol 0.564 9.8 ,0.01
86 Hexanal 0.633 7.0 ,0.01
109 Heptanal 0.671 13.6 ,0.01
110 3-Methyl-1-butanol 0.608 14.0 ,0.01
Lung cancer vs. healthy subjects.
doi:10.1371/journal.pone.0114555.t003
Fig. 2. Decision tree algorithm to discriminate between healthy and lung cancer patients.
doi:10.1371/journal.pone.0114555.g002
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Fig. 3. Box-and-whisker plots of peak-2 between healthy and lung adenocarcinoma patients. Peak 2
was significantly higher in patients with lung cancer (p,0.001). The box represents the 25th and 75th
percentiles, the whiskers represent the range, and the lined box represents the median, whereas circles
represent the mean. Lung adenocarcinoma patients revealed a significantly higher n-Dodecane VOC peak
than healthy volunteers and the n-Dodecane VOC peak could separate values with a sensitivity of 81.3% and
a specificity of 89.7%.
doi:10.1371/journal.pone.0114555.g003
Fig. 4. Box-and-whisker plots showing the IMS signal intensity of peak-2 in adenocarcinoma patients
positive and negative for EGFR. Fourteen patients with EGFR mutation displayed a significantly higher n-
Dodecane peak with a sensitivity of 85.7% and a specificity of 78.6% (p,0.01) than in 14 adenocarcinoma
patients without the EGFR mutation.
doi:10.1371/journal.pone.0114555.g004
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60.0% (p,0.001). Comparing VOC peaks between small cell carcinoma and
healthy subjects, peak-6 was found to be significantly higher than 95% (p,0.01)
with a sensitivity of 97.4% and a specificity of 50.0%. In addition, a decision tree
algorithm could separate histological types of lung cancer and healthy volunteers
(Fig. 6).
Discussion
In this prospective study, VOC peak patterns using a decision tree algorithm were
useful in the detection of lung cancer. We found that some VOC peaks displayed
significant differences between patients with adenocarcinoma, squamous cell
carcinoma, small cell carcinoma and healthy volunteers. In addition, some VOC
peaks positive for the EGFR mutation displayed significant increases, especially
the n-Dodecane peak, which was the most valuable biomarker. VOC analysis
using IMS is expected to be an important detection test for lung cancer. To our
knowledge, this is the first study to show that n-Dodecane analysis from
adenocarcinoma patients might be useful to discriminate for the EGFR mutation.
VOC analysis of lung cancer using GC/MS has been used extensively since 1985.
In GC/MS, some VOC models were used to analyze significance, with a sensitivity
and specificity of 54 to 100% and 67 to 100%, respectively [35]. Westhoff et al.
was the first to report VOC analysis for lung cancer using IMS. He reported that
23 VOC peaks from exhaled breath could separate lung cancer and a healthy
control, unaffected by smoking history [11]. However, spectrometry technologies
using breath sampling were affected by ambient conditions, oral odor and
nutrition. Direct airway sampling under bronchoscopy was negligible for oral
odor and some VOC peaks displayed significant differences between the lung
tumor site and the normal site. Moreover, some VOC peaks, 2-Butanol,
Fig. 5. IMS chromatogram in patients with lung adenocarcinoma positive for EGFR mutation (A) and negative for EGFR mutation (B).
doi:10.1371/journal.pone.0114555.g005
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2-Methylfuran and n-Nonanal, proved useful to separate adenocarcinoma and
squamous cell carcinoma [36–37]. For lung adenocarcinoma, n-Dodecane was
found to be an important VOC peak for both breath analysis and bronchoscopic
sampling and was reported to be associated to patients with lung cancer [36–37].
It is known that East Asian NSCLC patients have higher instances of EGFR
mutation [38–40]. Driver mutations, including EGFR, have focused on lung
cancer and other malignant tumors [41–43]. The EGFR mutation has a higher
instance than other driver mutations in lung cancer and is sensitive to the EGFR
tyrosine kinase inhibitor. The results of this study show that lung adenocarcinoma
positive for the EGFR mutation tends to increase the intensity of some VOC peaks
using IMS. EGFR may have a specific metabolism that may produce various
VOCs. The detection of EGFR mutation needs surgical specimen, bronchoscopic
or CT-guided needle biopsy tissue, bronchial lavage fluid and pleural effusion
with tumor cell. A previous study reported exhaled breath condensate could
evaluate EGFR mutation. However it was still difficult to detect EGFR mutations
in exhaled breath condensate because cellular components presented in exhaled
breath condensate are not representative of the tumor [44–45]. The analysis of
VOC patterns including a decision tree algorithm may be useful to detect EGFR
mutation emitted from lung cancer cell lines in the future.
This study had some limitations. First, the sample size was small and larger
sample studies are required. Although more patient breath samples are needed to
overcome potential problems with statistical investigations, in previous literature
sample sizes for breath analysis had been smaller when compared to the present
study [36–37]. Beside the major question to have more breath samples of patients
Fig. 6. A decision tree algorithm could separate small cell carcinoma, squamous cell carcinoma and
adenocarcinoma.
doi:10.1371/journal.pone.0114555.g006
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than peaks to overcome potential problems with statistical investigations in
general, here 89 samples were investigated and 115 peaks were found. Second,
VOCs in patients with lung cancer may be affected by smoking history. It should
be noted, if the differences were not related to tobacco smoking in lung cancer
patients, which was considered in detail by Westhoff et al. [11] showing, that in
both groups including a higher number of smokers and non-smokers the
differentiation using ion mobility spectrometry was successful. For the molecules
investigated by IMS in this study, the differences were independent of smoking
status and significant for both groups. In the study of Westhoff et al. [11]. there
was no database available to identify the analysis. Recently, Darwiche et al. [36]
showed by comparison of measurements taking samples of air from the same
patient at the cancer site and non-cancer site during bronchoscopy, differences
found were related to the place the sample was taken, directly over cancer cells or
on the other lung site. Third, in accordance with Japanese regulations, restrictions
of 63Ni b-radiation sources of under 100 MBq have been set for this Japanese pilot
study, which is lower than European restrictions. However, the current study
results show that IMS with a 95 MBq b-radiation source could discriminate
between healthy volunteers and patients with lung cancer successfully. Therefore,
creating a database for the Asian population in relation to VOC peaks and
substances may be required. In future studies, multi-center trials using IMS are
needed to analyze lung cancer.
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